RECORD STRONG END TO 2019
Oslo, Norway (19 February 2020) NattoPharma increased revenues by 25% in the fourth quarter and for the full year 2019. Adjusted EBITDA in the quarter came in at NOK 5,0 million. (mnok) Q4’19 Q4’18 2019 2018Operating Revenue 38,5 30,9 127,1 101,7Gross Margin 42,4% 43,4% 42,2% 43,1%EBITDA (adj.) 5,0 3,0 11,0 6,7 CEO, Kjetil Ramsøy: “We are very happy to deliver on our promises and continue the growth curve we have seen in the last couple years. The growth continues in all areas and across all product categories. We see